Global $221 Billion Biologics Market Opportunities and Strategies 2018-2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Biologics Global Market Opportunities And Strategies To 2021” report has been added to ResearchAndMarkets.com’s offering.
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines.
Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances. In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan.
There are over 1000 biologics under development which will drive the biologics market in the future. Cancer is the therapeutic area with maximum number of biologics under development and Alzheimer’s has the least number.
The number of biosimilars being approved is on the rise and is likely to affect the overall growth of biologics market globally, by expanding the market, but also by reducing average pricing. Currently, the ratio of biosimilars to biologics sold is quite similar in European Union (EU) and the USA (4% biosimilars and 96% biologics). In Japan and India, the proportion of biosimilars is higher in these markets, almost 13-19%, compared to EU and the USA.
Key Topics Covered:
1. Executive Summary
2. Biologics Market Characteristics
3. Biologics Market Size And Growth
4. PESTLE Analysis
5. Biologics Market Segmentation
6. Global Biologics Market Trends And Strategies
7. Global Biologics Market Compared With Similar Markets, 2017
8. Global Biologics Market Segment Details
9. Biologics Market Geography Regional and Country Analysis
10. Global Biologics Market Comparison With Macro Economic Factors
11. Biologics Market Comparison With Industry Metrics
12. Biologics Market Regional And Country Analysis
19. Biologics Market Competitive Landscape
20. Biologics Market Key Mergers And Acquisitions
Asia-Pacific:3S Bio Asahi Glass Co. Ltd. Biocon China Biologic Products Holdings Inc. Dr. Reddy’s Laboratories Shanghai Fosun Pharmaceutical Group Wockhardt Zydus Cadila
North America:Abbvie Biogen Idec Johnson & Johnson Pfizer Roche
Western Europe:3P Biopharmaceuticals 4SC AG AstraZeneca Bayer Boehringer Ingelheim Cinfa Biotech Fareva GlaxoSmithKline Hikma Pharmaceuticals Ipsen Merck Mologen Pierre Fabre Medicament Sanofi
South America:Ach Eurofarma Hypermarcas Teuto Brasileiro
Middle East:Hikma Pharmaceuticals Julphar Pfizer
Africa:Altis Biologics Sanofi Genzyme Eastern Europe: Geropharm Microgen NovaMedica SynBio Valenta
For more information about this report visit https://www.researchandmarkets.com/research/xvc5wx/global_221?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005325/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/27/2018 04:59 AM/DISC: 09/27/2018 04:59 AM